after a certain distance they are recombined again in an output optical waveguide. In one of the arms, a sensor area houses the specific bioreceptor. The phase shift between the two arms is measured to determine the extent of the molecular interactions occurring in the sensor area. To obtain single-mode behavior, the parameters of the waveguide must be carefully chosen.
The sensor has been applied to real-time and label-free detection of single DNA point mutations in the BRCA-1 gene, which can identify women who are predisposed to developing breast cancer. The MZI-based sensor successfully discriminated between normal and mutant sequences and demonstrated a limit of detection in the picomolar range for fully hybridized DNA and a limit of detection in the nanomolar range for singlepoint mutations.
For the lab-on-a-chip development, the sensors have been integrated with a microfluidic network at the wafer level. The microflow cells-see Figure 2 embedded microchannel network fabricated using enhanced CMOS-compatible SU-8 photoresist multilevel polymer technology on top of a wafer containing the MZI nanophotonic biosensor devices. The platform can operate at pressure drops up to 1000kPa under steady-state flow rates ranging from 1 to 1000µl/min in the laminar flow regime. 2 Further development of biosensing microsystem platforms based on the integration of MZI, microfluidics, and optical detectors will lead to significant advances in clinical diagnostics. Currently, we are developing the technology for direct fabrication of grating couplers onto the waveguides for light diffraction and coupling, which promises significant increases in sensitivity. 3 In the future, fabrication of nano/macrosystems with hybrid integration of light sources, photodetectors, transducers, microfluidics, and electronic functions will offer the possibility of diagnostic tools with increased sensitivity, specificity, and reliability for early disease detection.
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